Aug 01, 2024 / 08:30PM GMT
Operator
Good afternoon, ladies and gentlemen, and welcome to the Longboard Pharmaceutical earnings and incorporate update Call. As a reminder, this conference call is being recorded.
I would now like to turn the call over to Brandi Roberts, Longboard's Chief Financial Officer. You may begin.
Brandi Roberts - Longboard Pharmaceuticals Inc - Chief Financial Officer, Executive Vice President
Thank you, and good afternoon, everyone. Welcome to Longboard's conference call and webcast where we'll be providing a corporate update, including results from our LP659 single-ascending dose study.
Before we begin today, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company, including without limitation, statements about the potential of our product candidates, the anticipated timing and design of clinical trials, top line data, commercial opportunities and financial guidance. These statements are subject to risks and uncertainties that could cause actual results to differ.
Factors
Q2 2024 Longboard Pharmaceuticals Inc Earnings Call and Discussion of Topline Phase 1 SAD Data for LP659 Transcript
Aug 02, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers